Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Azacitidine + DSP107 + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Azacitidine||Vidaza||azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg||DNMT inhibitor (Pan) 5||Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov).|
|DSP107||DSP-107|DSP 107|SIRPa-4-1BBL DSP107|SIRPa 4-1BBL DSP107||DSP107 is a bi-functional trimeric fusion protein that consists of extracellular domains of SIRP alpha and 4-1BBL, which blocks the interaction between CD47 and SIRP alpha, and simultaneously activates the co-stimulatory receptor 4-1BB, potentially activating innate and adaptive immune responses, and inducing cytotoxicity and phagocytosis of tumor cells (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A076; Blood (2020) 136 (Supplement 1): 19-20).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 24||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04937166||Phase I||Azacitidine + DSP107 + Venetoclax||A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies||Recruiting||USA||0|